Biosignal animal studies show efficacy

Biosignal (ASX:BOS) has confirmed the efficacy of its furanone molecules in preventing bacterial colonisation of contact lenses in animal studies, paving the way for more extensive human studies.

The proof-of-concept study -- a collaboration with the Institute for Eye Research -- demonstrated that after 24 hours of continuous wear, furanone-coated lenses maintained their efficacy, reducing bacterial adhesion by 70 per cent, as well as reducing production of bacterial toxins. In addition, there was a reduction of indicators for two eye conditions associated with contact lens wear, contact lens-induced peripheral ulcer (CLPU) and microbial keratitis (MK).

The results from the pre-clinical trial will also underpin current efforts to secure commercial partners for the technology, said CEO Michael Oredsson.

"Biosignal's partner in this field, the Institute for Eye Research, and Biosignal are currently in discussions with contact lens manufacturers who seek technologies that enable completely problem-free extended wear of contact lenses. Such antibacterial technologies are currently not commercially available," he said.

Oredsson said that the company was planning to do a safety study in humans next year.